Multi-dose Vials

SNAP-8 (Acetyl Octapeptide-3) is an 8-amino acid biomimetic peptide (Ac-EEMQRRAD-NH2) that competitively inhibits SNAP-25 incorporation into the SNARE complex, achieving ~43% inhibition of glutamate release. Developed as a topical alternative to botulinum toxin, it provides muscle relaxation (not paralysis) with reversible, dose-dependent modulation of neurotransmitter release.

• Thymosin Beta-4 Derivative: 43-amino acid peptide (Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES-OH), derived from naturally occurring thymosin beta-4 (70-80% of beta-thymosins), 2,000+ publications, N-terminal acetylation for enhanced stability
• Multi-Pathway Regeneration: G-actin sequestration (Kd 0.5-0.7 μM), cell migration promotion, VEGF upregulation via Wnt/β-catenin/Lef-1, angiogenesis, PI3K/Akt/eNOS survival pathway, anti-fibrotic via TGF-β1 suppression
• Clinical Status: No FDA-approved human drug, all therapeutic data preclinical (wound healing, cardiac repair, pulmonary fibrosis, Alzheimer's neuroprotection), extensive safety profile in animal models

• 28-Amino Acid Immunomodulator: N-terminal fragment of prothymosin alpha (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN), originally isolated from thymus 1977, 3,000+ publications, thymalfasin (Zadaxin) approved in 35+ countries
• Pleiotropic Immune Activation: TLR2/3/4/7/9 agonist, dendritic cell activation, T-cell maturation (CD4+/CD8+), Th1 polarization (IL-2/IL-12/IFN-γ↑), NK cell enhancement, PD-1/Tim-3 exhaustion marker reduction
• Clinical Status: FDA orphan drug (DiGeorge anomaly, melanoma, hepatitis B, HCC), China approved for hepatitis B/HCC, COVID-19 mortality reduction (11.11% vs 30.00%, Liu et al. 2020), sepsis meta-analysis 41% mortality reduction